002422 Share Price Performance
CN¥34.61
4.76 (15.95%)
6.9% overvalued intrinsic discount
CN¥32.38
Fair Value
Price CN¥34.61
AnalystLowTarget CN¥32.38
AnalystConsensusTarget CN¥40.92
AnalystHighTarget CN¥46.00
Fair ValueCN¥32.38
Share Pricen/a
Sichuan Kelun Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
002422 Community Narratives
AN
Fair Value CN¥32.38 6.9% overvalued intrinsic discount
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CN¥40.59 14.7% undervalued intrinsic discount
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CN¥46 24.8% undervalued intrinsic discount
Rising Middle Class And Aging Populations Will Expand Drug Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
Key Takeaways Expanding innovative drug pipeline and commercial launches, underpinned by rapid insurance uptake, drive strong growth in recurrent and high-visibility revenues. International partnerships and broad innovation investments enhance earnings potential, margin expansion, and global market presence.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CN¥40.59
14.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
11.14% p.a.
Profit Margin
15.69%
Future PE
21.93x
Share price in 2028
CN¥49.37
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
Key Takeaways Growing pricing pressure, regulatory uncertainties, and rising compliance costs threaten future sales growth, profitability, and international revenue potential. Heavy R&D spending, reliance on legacy products, and tightening ESG requirements may erode market share and strain operational margins over time.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CN¥32.38
6.9% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
6.58% p.a.
Profit Margin
12.99%
Future PE
21.37x
Share price in 2028
CN¥39.3
Rising Middle Class And Aging Populations Will Expand Drug Markets
Key Takeaways Accelerated new therapy launches, global partnerships, and innovative drug focus could drive earnings growth and margin expansion beyond current expectations. Expanding domestic reach and overseas market entry, coupled with policy agility and strong financials, may unlock sustained revenue growth and defensible earnings.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CN¥46
24.8% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
15.18% p.a.
Profit Margin
15.29%
Future PE
20.44x
Share price in 2028
CN¥55.83
Snowflake Analysis
Sichuan Kelun Pharmaceutical Co., Ltd. Key Details
About 002422
- Founded
- 1996
- Employees
- 21864
- CEO
- WebsiteView website
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion set, dispensing and injection syringes, detained needles, nebulizer, and vacuum blood collection tubes; over-the-counter products; and APIs for treatment of cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injection. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
